Roche and AbbVie to Compete with New Bispecific Antibodies for Lymphoma Market Share

Roche and AbbVie are set to compete in the lymphoma market with their newly approved bispecific antibodies (BsAbs). Four weeks after AbbVie's Epkinly was approved, the FDA has given its approval for Roche's Genentech's BsAb, Columvi. Both drugs will be available this summer, leading to a head-to-head competition between the two companies. These therapies utilize bispecific antibody design to bin..